These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26383765)

  • 1. Biotherapies in large vessel vasculitis.
    Pazzola G; Muratore F; Pipitone N; Salvarani C
    Rev Med Interne; 2016 Apr; 37(4):274-8. PubMed ID: 26383765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Standard and biological treatment in large vessel vasculitis: guidelines and current approaches.
    Muratore F; Pipitone N; Salvarani C
    Expert Rev Clin Immunol; 2017 Apr; 13(4):345-360. PubMed ID: 28116918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biotherapies in large vessel vasculitis.
    Ferfar Y; Mirault T; Desbois AC; Comarmond C; Messas E; Savey L; Domont F; Cacoub P; Saadoun D
    Autoimmun Rev; 2016 Jun; 15(6):544-51. PubMed ID: 26883459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recent advances in the treatment of large vessel vasculitides].
    Szabó MZ; Kiss E
    Orv Hetil; 2017 Jan; 158(1):5-12. PubMed ID: 28067080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does glucocorticosteroid-resistant large-vessel vasculitis (giant cell arteritis and Takayasu arteritis) exist and how can remission be achieved? A critical review of the literature.
    Kötter I; Henes JC; Wagner AD; Loock J; Gross WL
    Clin Exp Rheumatol; 2012; 30(1 Suppl 70):S114-29. PubMed ID: 22640655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological treatments in giant cell arteritis & Takayasu arteritis.
    Samson M; Espígol-Frigolé G; Terrades-García N; Prieto-González S; Corbera-Bellalta M; Alba-Rovira R; Hernández-Rodríguez J; Audia S; Bonnotte B; Cid MC
    Eur J Intern Med; 2018 Apr; 50():12-19. PubMed ID: 29146018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tocilizumab: a new therapy for large vessel vasculitis.
    Al-Homood IA
    Clin Exp Med; 2014 Nov; 14(4):355-60. PubMed ID: 23949338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis.
    Hellmich B; Agueda A; Monti S; Buttgereit F; de Boysson H; Brouwer E; Cassie R; Cid MC; Dasgupta B; Dejaco C; Hatemi G; Hollinger N; Mahr A; Mollan SP; Mukhtyar C; Ponte C; Salvarani C; Sivakumar R; Tian X; Tomasson G; Turesson C; Schmidt W; Villiger PM; Watts R; Young C; Luqmani RA
    Ann Rheum Dis; 2020 Jan; 79(1):19-30. PubMed ID: 31270110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors.
    Matsumoto K; Suzuki K; Takeshita M; Takeuchi T; Kaneko Y
    Front Immunol; 2023; 14():1197342. PubMed ID: 37197652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostics and treatment of large vessel vasculitis].
    Bauer CJ; Schäfer VS
    Inn Med (Heidelb); 2024 Feb; 65(2):107-113. PubMed ID: 38240814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reducing the Toxicity of Long-Term Glucocorticoid Treatment in Large Vessel Vasculitis.
    Palmowski A; Buttgereit F
    Curr Rheumatol Rep; 2020 Oct; 22(12):85. PubMed ID: 33047263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing treatment options for large vessel vasculitis.
    Macaluso F; Marvisi C; Castrignanò P; Pipitone N; Salvarani C
    Expert Rev Clin Immunol; 2022 Aug; 18(8):793-805. PubMed ID: 35714219
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic treatment of large-vessel vasculitides.
    Schäfer VS; Zwerina J
    Curr Opin Rheumatol; 2012 Jan; 24(1):31-7. PubMed ID: 22089099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel therapeutic strategies for large vessel vasculitis.
    Koening CL; Langford CA
    Rheum Dis Clin North Am; 2006 Feb; 32(1):173-86, xi. PubMed ID: 16504829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Large vessel vasculitis].
    Weigand S; Fleck M
    Z Rheumatol; 2014 Jun; 73(5):447-55; quiz 456-7. PubMed ID: 24924731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated with Relapse and Dependence on Glucocorticoids in Giant Cell Arteritis.
    Dumont A; Parienti JJ; Delmas C; Boutemy J; Maigné G; Martin Silva N; Sultan A; Planchard G; Aouba A; de Boysson H
    J Rheumatol; 2020 Jan; 47(1):108-116. PubMed ID: 30877210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in the clinical management of giant cell arteritis and Takayasu arteritis.
    Koster MJ; Matteson EL; Warrington KJ
    Curr Opin Rheumatol; 2016 May; 28(3):211-7. PubMed ID: 26885650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcomes of large vessel arteritis.
    Borg FA; Dasgupta B
    Best Pract Res Clin Rheumatol; 2009 Jun; 23(3):325-37. PubMed ID: 19508941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of leflunomide in the management of large vessel vasculitis: A systematic review and metaanalysis of cohort studies.
    Narváez J; Estrada P; LLop D; Vidal-Montal P; Brugarolas E; Maymó-Paituvi P; Palacios-Olid J; Nolla JM
    Semin Arthritis Rheum; 2023 Apr; 59():152166. PubMed ID: 36645992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medium- and Large-Vessel Vasculitis.
    Saadoun D; Vautier M; Cacoub P
    Circulation; 2021 Jan; 143(3):267-282. PubMed ID: 33464968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.